2023-10-23 10:07:00
Amal Allam wrote Monday, October 23, 2023 01:07 PM
The British newspaper “Daily Mail” revealed a new group of drugs that brings hope of treatment for men with prostate cancer in its final stages. 7 pills a day brought Andy, 51 years old, from the brink of death. Andy Willis was given a lifeline following he was diagnosed with… Prostate cancer .
Eliminate prostate cancer
The newspaper added that a man has only years left to live following he was diagnosed with aggressive and incurable prostate cancer, and he is now on the verge of becoming tumor-free just months following starting… Drug treatment The revolutionary.
In April, Andy Willis became one of the first people ever to receive the experimental treatment following being told his cancer was too advanced for conventional treatment. The 51-year-old now takes seven pills a day – with no side effects, and most importantly. , that scans reveal that it has become free of Cancer It is currently undetectable.
Andy says, “I was given the opportunity to take this medication when I was sick and weak, and within weeks of starting treatment, the pain subsided and I gained more energy. I feel like I have my life back.”
The new drug, called AZD5305, is a type of cutting-edge pill known as a polyadenosine diphosphate ribose polymerase (PARP) inhibitor, designed to kill cancer cells by preventing them from self-repairing.
Another PARP inhibitor, called olaparib, has been approved for some NHS patients with prostate cancer and…breast cancer Earlier this year, the game-changing drug is also used to treat a number of other forms of the disease, including ovarian and fallopian tube cancer.
However, regarding half of patients taking olaparib will develop anemia – a low level of red blood cells causes fatigue and reduces the effectiveness of cancer treatment. Almost all people taking olaparib who develop the condition must stop taking the medicine.
But AZD5305 is designed to significantly reduce the risk of anemia, revealing a new option for this group.
“PARP inhibitors, such as olaparib, have proven to be very successful for cancer patients, especially those with advanced disease,” says Dr Andrew Hudson, a consultant clinical oncologist at the Christie NHS Foundation Trust in Manchester, “but it carries a high risk of side effects.” Olaparib also affects proteins in the bone marrow, where blood cells are produced, and there is little we can do to reduce the risks of this.
However, AZD5305 does not appear to do that, explains Dr. Hudson: “We hope it will help younger patients with aggressive prostate cancer have a better quality of life.”
Prostate cancer is the most common form of the disease in men, with 52,000 new cases diagnosed each year. The majority occur in men over the age of 65 who have slow mobility. Many patients will never need treatment because the disease does not threaten their health. .
However, regarding a tenth of patients have an aggressive form of the disease, which, even when detected early, spreads rapidly and quickly becomes fatal. Prostate cancer is usually hereditary – caused by defects in the genes of those affected – and affects younger men, and these patients make up a large proportion. Of the around 12,000 Britons who die from prostate cancer each year, around half of men with advanced prostate cancer live less than 5 years.
In April, patients with a certain type of hereditary aggressive prostate cancer, caused by a BRCA gene mutation, were given the opportunity to receive olaparib, and experts claim there are other people with hereditary forms of cancer who might eventually benefit as well, Dr. Hudson says. “We know from studies that patients with damaged DNA respond better to PARP inhibitors,” BRCA is one example of this.
AZD5305 is designed to be taken daily along with another pill called enzalutamide, which blocks the effects of testosterone on the cells. Prostate cancer.
During the early phase of the trial, which is being conducted at Christie NHS Foundation Trust and other hospitals around the world, a small number of prostate cancer patients receive the drug in order to analyze the risk of developing anemia. If the trial shows that the drug significantly reduces its incidence, the next step will be A larger trial to determine whether it can be offered to patients as an alternative to olaparib.
Dr Hudson says that although it is too early to conclude whether the drug will be available on the NHS, he is surprised by Andy’s response.
He added, “It is certainly better than we would have expected if he had been taking only enzalutamide, and most importantly, he did not suffer from any serious side effects,” explaining, “We are entering a new era for the treatment of aggressive prostate cancers, thanks to drugs such as PARP inhibitors, where these patients now live.” For a number of years, they continue to work and live a fairly normal life.
But this depends on them not experiencing side effects, including anaemia. A drug that might help avoid this risk would make a big difference. Most importantly, scans and blood tests reveal that cancer It has shrunk to the point of being almost undetectable.
1698074828
#Hope #prostate #cancer #patients #pills #change #tumor #patients
